Remove Chemotherapy Remove Download Remove HIV Treatment and Prevention Agents
article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. 2 Vepdegestrant is an oral PROTAC that targets ER and is the first agent of its type to be evaluated in a phase 3 trial.

article thumbnail

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.